Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 3Prostatic Neoplasms 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Kidney Neoplasms 2Hodgkin Disease 2Carcinoma, Renal Cell 2Breast Neoplasms 2von Hippel-Lindau Disease 1Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocythemia, Essential 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Doxorubicin 6Trabectedin 5pazopanib 4Radiotherapy 4ribociclib 3pembrolizumab 3palbociclib 3Gemcitabine 3brostallicin 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Immunoglobulin G 2Imatinib Mesylate 2Ifosfamide 2Docetaxel 2Dexamethasone 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1tanespimycin 1talimogene laherparepvec 1sotigalimab 1soblidotin 1sitravatinib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma × tanespimycin × Clear all
NCT00969917 2015-04-14

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Withdrawn
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡